2701 Kent Avenue West Lafayette, Indiana, 47906 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

16100 Chesterfield Pkwy W, Chesterfield, MO, 63017 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

10424 Middle Mt Vernon Rd Mt Vernon, IN, 47620 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

10424 Middle Mt Mt Vernon, IN, 47620 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

10424 Middle Mt Vernon Rd Mt Vernon, IN , 47620 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

10424 Middle Mt Mt Vernon, IN , 47620 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

2701 Kent Avenue West Lafayette, IN, 47906 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

111 10th Avenue South, Suite 102 Nashville, TN, 37203 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

15 Firstfield Rd Gaithersburg, MD, 20878 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

16100 Chesterfield Parkway West Suite 325 Chesterfield, MO, 63017 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

1512 Webster Ct Fort Collins, CO, 80524 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

7581 W 103rd Ave #300 Westminster, CO, 80021 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.

19 Worthington Access Drive Maryland Heights, MO, 63043 United StatesAs your laboratory partner, Inotiv provides a broad array of nonclinical and analytical services, as well as a deep knowledge of the drug discovery & development continuum that will exceed your expectations. From early in vitro and in vivo pharmacology models supporting therapeutic areas such as: Arthritis (OA/RA) Hepatic Systemic Lupus Cardio-renal IBD/GI Neurosciences Cardiovascular Inflammation Pulmonary Hepatitis B Immunology Renal Integrating your DMPK, toxicology and safety pharmacology, histopathology and image analysis, biomarker, and bioanalytical needs, we can help steer your program and equip you with strategic insights that enable informed decisions sooner. Take advantage of our extensive and impeccable regulatory history, world-class team of scientists, and authentic passion for discovering life-saving therapeutics. By partnering with Inotiv, expect more attention, more insight, and a superlative experience as we deliver stage-relevant solutions essential to meeting your program’s milestones. Inotiv’s Target Sufficiency platform analyzes the protein drug targets of diverse therapeutic approaches (small molecule, biologics, RNA therapeutics, gene editing, targeted protein degradation and cell therapeutics) across a wide range of diseases, including oncology, metabolic, autoimmune and neurodegenerative diseases. We use high resolution mass spectrometry (MS) technology to precisely measure drug target proteins and the protein pathways and networks in which they function. Target Sufficiency provides highly specific biomarkers from discovery through clinical trials. Our MS analyses quantify proteins in all specimen types, including plasma/serum and other fluids, cells and other in vitro models, and tissues, including formalin-fixed, paraffin-embedded (FFPE) sections and needle biopsies. We can systematically develop an assay for any protein or any protein form, without a requirement for antibodies or other affinity reagents. Our bioinformatics platforms translate our data to practically useful biological interpretation. We partner with client teams to customize analyses for measurement of any protein form, including post-translationally modified, sequence variant, splice isoform and gene-edited proteins. We can also quantify proteins, such as editing nucleases resulting from delivery of mRNA, thereby assessing the effectiveness and quantify tissue specificity of gene delivery systems. We can analyze FFPE tissues from archival clinical trial specimens to retrospectively analyze proteins, proteome pathways and networks associated with response/safety phenotypes or other trial outcomes. We can analyze specimens from Inotiv in-life studies to add value to these offerings.